share_log

Avant and IMC Execute BLK MKT Trademark Licensing Agreement for the German Medical Cannabis Market

Avant and IMC Execute BLK MKT Trademark Licensing Agreement for the German Medical Cannabis Market

Avant 和 IMC 为德国医用大麻市场执行 BLK MKT 商标许可协议
PR Newswire ·  04/04 07:30

TORONTO, GLIL YAM, Israel and KELOWNA, BC., April 4, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, and Avant Brands Inc. (TSX: AVNT) (OTCQX: AVTBF) (FRA: 1BU0) ("Avant") a leading producer of innovative cannabis products, jointly announce the signing of an international trademark licensing agreement (the "Licensing Agreement") granting Adjupharm GmbH, IMC's German subsidiary ("Adjupharm" or "IMC Germany", as applicable), the exclusive right to launch the BLK MKT brand in the German medical cannabis market. The Licensing Agreement constitutes another major milestone with respect to the relationship between the two cannabis companies.

多伦多,GLIL YAM,以色列和不列颠哥伦比亚省基洛纳,2024 年 4 月 4 日 /PRNewswire/ — IM Cannabis Corp.(CSE:IMCC)(纳斯达克股票代码:IMCC)(the”公司“,”我大麻“,或”IMC“),一家在以色列和德国开展业务的领先医用大麻公司,以及Avant Brands Inc.(多伦多证券交易所股票代码:AVNT)(OTCQX:AVTBF)(FRA:1BU0)(”前卫“)领先的创新大麻产品生产商,共同宣布签署国际商标许可协议(”许可协议“) 授予 IMC 的德国子公司 Adjupharm GmbH(”Adjupharm“或”IMC 德国“,视情况而定),推出 BLK MKT 的专有权利 德国医用大麻市场的品牌。许可协议是两家大麻公司之间关系的又一个重要里程碑。

Under the terms of the Trademark License Agreement, Avant's subsidiary will grant IMC Germany the license to utilize Avant's BLK MKTTM cannabis brand for use on their medical cannabis products. All such products will contain cannabis cultivated exclusively by Avant and subsequently exported to Germany. The collaboration between the two companies anticipates a positive outcome in the emerging German medical cannabis market, especially following the recent legalization by the government on April 1st.

根据商标许可协议的条款,Avant的子公司将授予德国IMC使用Avant的BLK MKT的许可TM 用于其医用大麻产品的大麻品牌。所有这些产品都将包含由Avant专门种植并随后出口到德国的大麻。两家公司之间的合作预计德国新兴医用大麻市场将取得积极成果,尤其是在政府最近于4月1日合法化之后st

The Licensing Agreement signals IMC's commitment to implementing a premium strategy in Germany as well as in Israel and acts as another step to establish Avant's position in the ultra-premium segment in Israel and Germany. IMC and Avant have had a productive partnership so far, combining Avant's premium cannabis products with IMC's sales, marketing and distribution expertise in Israel. Both companies believe the Licensing Agreement will enhance the companies' capabilities to meet the demands of the German market.

该许可协议表明了IMC承诺在德国和以色列实施溢价战略,也是确立Avant在以色列和德国超高端细分市场地位的又一步。到目前为止,IMC和Avant建立了富有成效的合作伙伴关系,将Avant的优质大麻产品与IMC在以色列的销售、营销和分销专业知识相结合。两家公司都认为,许可协议将增强两家公司满足德国市场需求的能力。

"By evolving our partnership with Avant, we continue to improve our supply chain and ability to provide ultra-premium, quality brand and product to the German medical cannabis market," Oren Shuster, CEO of IMC commented.

“通过发展与Avant的合作伙伴关系,我们将继续改善我们的供应链和向德国医用大麻市场提供超优质、优质的品牌和产品的能力,” 奥伦·舒斯特,IMC首席执行官评论道。

"We believe that our collaboration with Avant will continue to accelerate the strong momentum we have established in the German medical cannabis market," stated Richard Balla, CEO of IMC Germany.

他说:“我们相信,我们与Avant的合作将继续加速我们在德国医用大麻市场建立的强劲势头。” 理查德·巴拉, 德国IMC首席执行官。

"This agreement represents another major milestone with respect to our highly successful multi-year partnership with IMC," said Norton Singhavon, CEO, Avant Brands.

他说:“该协议是我们与IMC非常成功的多年合作伙伴关系的又一个重要里程碑。” 诺顿·辛哈文,Avant Brands首席执行官。

"We are very excited to be working with IMC's German team" said David Lynn, COO, Avant Brands. "We are confident that they will do an outstanding job launching the BLK MKT brand in Germany".

他说:“我们很高兴能与IMC的德国团队合作。” 大卫·林恩,Avant Brands 首席运营官。“我们相信,他们将在德国推出BLK MKT品牌方面做得非常出色”。

Avant's three largest cultivation facilities all hold ICANN-GAP and GACP certifications; thus, Avant is positioned to potentially distribute its premium cannabis flower into international markets.

Avant最大的三个种植设施均拥有ICANN-GAP和GACP认证;因此,Avant有望将其优质大麻花分销到国际市场。

IMC Germany is the 6th largest distributor of medical cannabis flowers in Germany and is number 1 in sales per SKU, growing +180% in 2023.1

IMC Germany 是 6第四 德国最大的医用大麻花分销商,每个SKU的销售额排名第一,2023年增长了180%。1

1Insight Health December 2023

1洞察健康 2023 年 12 月

About IM Cannabis Corp.

关于 IM Cannabis

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

IMC(纳斯达克股票代码:IMCC)(CSE:IMCC)是一家国际大麻公司,为最大的两个医用大麻市场以色列和德国的医疗患者提供优质大麻产品。该公司最近退出了在加拿大的业务,将重点和资源转移到其最高价值的市场以色列和德国实现可持续和盈利的增长。该公司利用由独特的数据驱动方法和全球来源的产品供应链提供支持的跨国生态系统。公司坚定不移地致力于负责任的增长并遵守最严格的监管环境,努力扩大其商业和品牌力量,成为全球高质量的大麻生产商。

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

IMC生态系统通过与Focus Medical Herbs Ltd.的商业关系在以色列运营。Focus Medical Herbs Ltd.利用多年的专有数据和患者见解向医疗患者进口和分销大麻。该公司还在以色列经营医用大麻零售药房、在线平台、配送中心和物流中心,从而实现整个价值链中IMC产品的安全交付和质量控制。在德国,IMC生态系统通过Adjupharm GmbH运营,向药房分发大麻供医用大麻患者使用。直到最近,该公司还通过Trichome Financial Corp及其全资子公司在加拿大积极开展业务,为加拿大成人用途市场种植、加工、包装和销售优质和超优质大麻。该公司已退出在加拿大的业务,并认为这些业务已终止。

Disclaimer for Forward-Looking Statements

前瞻性陈述的免责声明

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to statements relating to compliance with Nasdaq's continued listing requirements, and timing and effect thereof and the potential for an extension to regain compliance; Company leaving the Canadian cannabis market to focus on Israel, Germany and Europe and the potential outcome of the Licensing Agreement and the effect of collaboration with Avant in the German market.

本新闻稿包含适用的加拿大和美国证券法规定的前瞻性信息或前瞻性陈述(统称为 “前瞻性陈述”)。涉及我们预计将来发生的活动或发展的所有信息均为前瞻性陈述。前瞻性陈述通常使用 “寻求”、“预测”、“相信”、“计划”、“估计”、“预期”、“可能” 和 “打算” 等词语来识别,以及关于某一事件或结果 “可能”、“将”、“应该”、“可能” 或 “可能” 发生或实现的陈述以及其他类似的表述。前瞻性陈述基于管理层在陈述发表之日的估计和意见。在新闻稿中,此类前瞻性陈述包括但不限于与遵守纳斯达克持续上市要求有关的陈述、其时机和影响,以及延期以恢复合规的可能性;公司离开加拿大大麻市场专注于以色列、德国和欧洲,以及许可协议的潜在结果以及与Avant合作在德国市场的影响。

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East.

上述前瞻性陈述和假设清单并不详尽。由于前瞻性陈述涉及未来的事件和状况,因此就其本质而言,它们涉及固有的风险和不确定性。由于多种因素和风险,实际结果可能与此类前瞻性陈述目前的预期或暗示的结果存在重大差异。其中包括:公司未能遵守监管严格的行业中适用的监管要求;公司运营所在司法管辖区的政府政策和法规的意外变化;公司继续满足加拿大证券交易所和纳斯达克资本市场的上市要求的能力;任何意外未能保持良好信誉或续订其执照;公司和Focus Medical(统称为 “集团”)兑现其销售承诺或增长的能力目标;集团依赖第三方供应协议提供足够数量的医用大麻以履行集团的义务;集团可能承担的责任风险、与之相关的风险水平以及涉及集团的任何诉讼或其他类似争议或法律诉讼的预期结果;竞争加剧的影响;缺乏并购机会;不利的市场条件;产量、质量和成本估算的固有不确定性以及潜在的意外成本和支出;使用集团大麻产品造成的产品责任和其他安全相关责任风险;供应链限制;对关键人员的依赖;拖欠现有债务的风险以及东欧和中东的战争、冲突和内乱。

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

本新闻稿中包含的任何前瞻性陈述均自本新闻稿发布之日起作出,并基于管理层在发布此类前瞻性信息之日的信念、估计、预期和观点。除非适用的证券法要求,否则公司不承担任何更新前瞻性陈述的义务。投资者不应过分依赖前瞻性陈述。本警示声明明确限制了本新闻稿中包含的前瞻性陈述。

Company Contact:

公司联系人:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

安娜·塔兰科,投资者与公共关系总监
IM 大麻公司
+49 157 80554338
[电子邮件保护]

Oren Shuster, CEO
IM Cannabis Corp.
[email protected]

首席执行官奥伦·舒斯特
IM 大麻公司
[电子邮件保护]

Logo -

徽标-

SOURCE IM Cannabis Corp.

来源 IM Cannabis公司

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发